Minghui Pharmaceutical (Hangzhou) Ltd
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS16
PHASE 3 / 2-37
RECRUITING11
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO11%
Delay Index: of 9 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Minghui Pharmaceutical (Hangzhou) Ltd on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| MHB018A NCT06989918 |
P3 | Active, not recruiting | Thyroid Associated Ophthalmopathies | 108 | 2026-12 (-2 mo) |
| MHB036C NCT06373406 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 200 | 2027-04 (+32 mo) |
| Interventional NCT07257185 |
P3 | Active, not recruiting | Thyroid Eye Disease (TED) | 150 | 2027-08-31 |
| MHB009C for Injection NCT07326488 |
P1/2 | Recruiting | Advanced Malignant Solid Tumor | 200 | 2028-02 |
| MH004 1.0% Ointment NCT07682506 |
P3 | Recruiting | Vitiligo | 405 | 2028-02-23 |
| MHB039A NCT06345482 |
P1/2 | Active, not recruiting | Advanced Solid Tumor | 196 | 2028-04-01 |
| MHB018A injection NCT07622121 |
P3 | Recruiting | Thyroid Eye Disease, TED | 135 | 2028-07 |
| MHB018A NCT07622108 |
P3 | Recruiting | Thyroid Eye Disease, TED | 84 | 2028-07 |
| MHB018A injection NCT07262476 |
P3 | Recruiting | Thyroid Eye Disease (TED) | 258 | 2029-01-31 |
| MHB046C NCT06985355 |
P1/2 | Recruiting | Advanced Solid Cancer | 200 | 2029-05 |
| MHB036C for Injection NCT07229599 |
P1/2 | Recruiting | Advanced Lung Cancer | 300 | 2029-05 |
| MHB088C for Injection NCT07126665 |
P1/2 | Recruiting | Advanced Malignant Solid Tumor | 116 | 2029-08 |
| MHB036C for Injection NCT07130383 |
P2 | Recruiting | Advanced Breast Cancer; Advanced Malignant Solid Tumor | 210 | 2029-08 |
| MHB042C for Injection NCT07192107 |
P1/2 | Recruiting | Advanced Malignant Solid Tumor | 200 | 2029-10 |
| MHB048C for Injection NCT07192120 |
P1/2 | Recruiting | mCRPC (Metastatic Castration-resistant Prostate Cancer); Advanced Malignant Solid Tumor | 200 | 2029-10 |
| MHB018A injection NCT07620405 |
P3 | Not yet recruiting | Thyroid Eye Disease (TED) | 219 | 2030-01 |